Objective: To describe the current data evaluating the efficacy and safety of memantine for the prevention of primary headache disorders. Data Sources: A literature search using MEDLINE (1966-July 2014) and EMBASE (1973-July 2014) was conducted using the search terms memantine, headache, migraine, glutamate, and NMDA. References of identified articles were reviewed for additional, relevant citations. Study Selection and Data Extraction: All English-language articles dealing with the use of memantine for prevention of primary headache disorders were included. Data Synthesis: Data from several retrospective reports and 2 prospective clinical trials suggest that memantine may be a useful treatment option for the prevention of primary headache disorders. The majority of available literature focuses specifically on chronic migraine prevention in refractory patients who had failed multiple previous prophylactic therapies. In these patients, 10 to 20 mg of memantine daily reduced the frequency and intensity of migraine headaches and was generally well tolerated, with few adverse events. Data regarding the efficacy of memantine for other primary headache disorders such as chronic tension type and cluster headaches are limited. Conclusion: Although further studies evaluating the efficacy of memantine for prevention of primary headache disorders are warranted, memantine may be a reasonable option, used either as monotherapy or adjunctive therapy, in the refractory chronic migraine prophylaxis setting.
StovnerLJHagenKJensenR. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27:193-210.
2.
National Institute of Health and Care Excellence (NICE). Headaches: diagnosis and management of headaches in young people and adults. http://www.nice.org.uk/guidance/cg150. Accessed July 25, 2014.
3.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629-808.
4.
SilbersteinSDHollandSFreitagF. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337-1345.
5.
PringsheimTDavenportWMackieG. Canadian Headache Society guidelines for migraine prophylaxis. Can J Neurol Sci. 2012;39(2, suppl 2):S1-S59.
6.
EversSAfraJFreseA. EFNS guideline on the drug treatment of migraine: revised report of an EFNS task force. Eur J Neurol. 2009;16:968-981.
7.
BendtsenLEversSLindeM. EFNS guideline on the treatment of tension-type headache: report of an EFNS task force. Eur J Neurol. 2010;17:1318-1325.
8.
EversSAfraJFreseA. Cluster headache and other trigemino-autonomic cephalgias. In: GilhusNEBarnesMPBraininM eds. European Handbook of Neurological Management. Vol 1, 2nd ed.Oxford, UK: Wiley-Blackwell; 2010:chap 11.
9.
ChenHSPellegriniJWAggarwalSK. Open-channel block of N-methyl-d-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci. 1992;12:4427-4436.
10.
PeetersMGunthorpeMJStrijbosPJ. Effects of pan- and subtype-selective NMDA receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine. J Pharmacol Exp Ther. 2007;321:564-572.
11.
BendtsenL. Central sensitization in tension-type headache: possible pathophysiological mechanisms. Cephalalgia. 2000;20:486-508.
12.
D’AndreaGD’ArrigoADalle CarbonareM. Pathogenesis of migraine: role of neuromodulators. Headache. 2012;52:1155-1163.
13.
AracavaYPereiraEFMaelickeA. Memantine blocks alpha7 nicotinic acetylcholine receptors more potently than N-methyl-d-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther. 2005;312:1195-1205.
14.
RammesGRupprechtRFerrariU. The N-methyl-d-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkylcyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a noncompetitive manner. Neurosci Lett. 2001;306:81-84.
15.
LindelofKBendtsenL. Memantine for prophylaxis of chronic tension-type headache–a double-blind, randomized, crossover clinical trial. Cephalalgia. 2009;29:314-321.
16.
BigalMRapoportASheftellFTepperDTepperS. Memantine in the preventive treatment of refractory migraine. Headache. 2008;48:1337-1342.
17.
SmithTRStonemanJMunsonP. Memantine for the prophylaxis of migraine: a report of 3 cases and discussion of pharmacology. Headache. 2005;16:167-170.
18.
SpengosKTheleritisCPaparrigopoulosT. Memantine and NMDA antagonism for chronic migraine: a potentially novel therapeutic approach?Headache. 2008;48:284-286.
19.
CharlesAFlippenCRomero ReyesM. Memantine for prevention of migraine: a retrospective study of 60 cases. J Headache Pain. 2007;8:248-250.
20.
CammarataDKruszJ. Memantine: novel mechanism for migraine and headache prophylaxis. Headache. 2005;45:820.
21.
VenturelliERaoRCharlesA. Memantine for prevention of cluster headache: a possible new treatment?J Headache Pain. 2010;11(suppl 1):S63.
22.
BendtsenLBigalMECerboR. Guidelines for controlled trials of drugs in tension-type headache: second edition. Cephalalgia. 2010;30:1-16.
23.
SchoenenJ. Guidelines for controlled trials of drugs in tension-type headache. First edition: International Headache Society Committee on clinical trials. Cephalalgia. 1995;15:165-179.
